博敏電子(603936.SH):擬終止公開發行可轉換公司債券
格隆匯5月11日丨博敏電子(603936.SH)公佈,公司於2022年5月11日召開第四屆董事會第二十次會議及第四屆監事會第十八次會議審議通過了《關於終止公開發行可轉換公司債券的議案》,同意公司終止經2021年第二次臨時股東大會批准的公司公開發行可轉換公司債券事項(以下簡稱“本次可轉債”)。
自公司本次可轉債方案公佈以來,公司董事會、經營管理層與中介機構一直積極推進各項工作。根據當前宏觀政策、市場環境變化等因素,結合公司戰略規劃和募投項目進程,經綜合評估,並與中介機構研究溝通和審慎分析,公司決定終止本次可轉債,同時將融資方式調整為非公開發行股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.